FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Source: 
CP Wire
snippet: 
  • ADPKD, the fourth leading cause of end-stage renal disease,1,2 is a progressively debilitating genetic disease characterized by the development of fluid-filled cysts in the kidneys
  • Data from two phase 3 clinical trials showed that Jynarque (tolvaptan) slowed kidney function decline in adults at risk of rapidly progressing ADPKD